公开(公告)号：US20250129166A1

公开(公告)日：2025-04-24

申请号：US18939765

申请日：2024-11-07

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Robert J. Johnston ,  Arvind Rajpal ,  Paul O. Sheppard ,  Luis Borges ,  Andrew Rankin ,  Keith Sadoon Bahjat ,  Alan J. Korman ,  Xiaodi Deng ,  Lin Hui Su ,  Ginger Rakestraw ,  Jason R. Pinckney ,  David A. Critton ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina G. Deyanova

IPC: C07K16/28 ,  A61K38/16 ,  C07K16/46

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

公开(公告)号：US11939383B2

公开(公告)日：2024-03-26

申请号：US17006670

申请日：2020-08-28

Applicant: Five Prime Therapeutics, Inc.

Inventor： Charles Kaplan ,  Alessandro Palumbo ,  Kathy Miller ,  Hangil Park ,  Nerissa Mendoza ,  Majid Ghoddusi

IPC: C07K16/18 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  G01N33/574

CPC classification number: C07K16/2827 ,  G01N33/57492 ,  C07K2317/56 ,  C07K2317/565 ,  G01N2333/70532

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4. The anti-B7-H4 antibodies or antigen-binding fragments thereof are useful, for example in detecting B7-H4. Immunohistochemistry (IHC) can be used to detect B7-H4. The present disclosure also provides methods for treating cancer wherein increased B7-H4 has been detected, by administering a therapeutic anti-B7-H4 antibody or antigen-binding fragment thereof.

公开(公告)号：US20240043542A1

公开(公告)日：2024-02-08

申请号：US18484986

申请日：2023-10-11

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/2827 ,  C07K16/2818 ,  A61P35/00 ,  G01N33/57492 ,  A61K2039/505

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US11789010B2

公开(公告)日：2023-10-17

申请号：US16608911

申请日：2018-04-27

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Brennan ,  Barbara Sennino ,  Susannah D. Barbee ,  Ursula Jeffry

IPC: G01N33/50 ,  G01N15/10 ,  G01N15/00

CPC classification number: G01N33/5011 ,  G01N15/10 ,  G01N2015/0065 ,  G01N2015/1006 ,  G01N2333/70532 ,  G01N2800/52

Abstract: This application relates to use of CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in methods of increasing the number of central memory T cells or for treatment for cancer or for use in cancer vaccine compositions.

公开(公告)号：US20230192870A1

公开(公告)日：2023-06-22

申请号：US17812592

申请日：2022-07-14

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Katherine E. Lewis ,  Serena Kimi Perna ,  Michael Carleton ,  Ke Xu ,  Penny Phillips ,  Dimple Pandya ,  Brian Wong ,  Julie Hambleton ,  Robert Sikorski ,  Emma Masteller ,  Kevin Hestir ,  David Bellovin ,  Janine Powers ,  Ernestine Lee

IPC: C07K16/28 ,  A61K47/69 ,  A61K47/64 ,  A61P35/00 ,  A61K31/337 ,  A61K31/513 ,  A61K31/7068 ,  A61K39/395 ,  C12Q1/6886

CPC classification number: C07K16/2866 ,  A61K47/6929 ,  A61K47/643 ,  A61P35/00 ,  A61K31/337 ,  A61K31/513 ,  A61K31/7068 ,  A61K39/3955 ,  C07K16/2818 ,  C12Q1/6886 ,  A61K2039/507

Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

公开(公告)号：US20230013293A1

公开(公告)日：2023-01-19

申请号：US17685056

申请日：2022-03-02

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US20220348657A1

公开(公告)日：2022-11-03

申请号：US17604505

申请日：2020-04-17

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Luis BORGES ,  Artur KARASYOV ,  Zheng MENG ,  Shawn RUSSELL ,  Nathan SALLEE ,  Hongbing ZHANG ,  Aileen ZHOU

IPC: C07K16/28 ,  C07K14/705 ,  G01N33/554

Abstract: Provided herein are components (e.g., cells and soluble proteins), systems, and methods for assessing the biological activity of soluble proteins comprising an Fc domain and a CD28-binding domain (e.g., CD80 extracellular domain Fc fusion proteins).

公开(公告)号：US20220168416A1

公开(公告)日：2022-06-02

申请号：US17554423

申请日：2021-12-17

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Harding ,  Kristen Pierce ,  Namrata Patil ,  Thomas Brennan ,  Julie Hambleton

IPC: A61K39/395 ,  C07K16/28 ,  A61K33/243 ,  A61K31/337 ,  A61K31/513 ,  A61K45/06

Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.

公开(公告)号：US11306150B2

公开(公告)日：2022-04-19

申请号：US16476814

申请日：2018-01-10

Applicant: Bristol-Myers Squibb Company ,  Five Prime Therapeutics, Inc.

Inventor： Robert J. Johnston ,  Andrew Rankin ,  Arathi Krishnakumar ,  Paul O. Sheppard ,  Arvind Rajpal

IPC: C07K16/28 ,  A61K45/06

Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.

公开(公告)号：US20210332137A1

公开(公告)日：2021-10-28

申请号：US17224865

申请日：2021-04-07

Applicant: Five Prime Therapeutics, Inc.

Inventor： Sandeep P. INAMDAR ,  Helen L. COLLINS ,  Hong XIANG ,  Xiang ZHANG ,  Neyssa MARINA

IPC: C07K16/28 ,  A61P35/00

Abstract: The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 to a subject in need thereof, for example, a cancer patient, in combination with a PD-1/PD-L1 antagonist, such as an anti-PD-1 antibody.